Effects of the COVID-19 pandemic on the number and characteristics of public drug program beneficiaries in Ontario, Canada
Bouck Z, McCormack D, Tadrous M, Campbell T, Gomes T. Canadian Health Policy. 2024; Jul 22 [Epub ahead of print].
Publications
Impact of COVID-19 on psychoactive medication use among individuals with intellectual and developmental disabilities in Ontario, Canada: a repeated cross-sectional study
Guan Q, Garg R, McCormack D, Lunsky Y, Tadrous M, Campbell T, Gomes T. Disabil Health J. 2024; Jun 12 [Epub ahead of print].
Mailed feedback to primary care physicians on antibiotic prescribing for patients aged 65 years and older: pragmatic, factorial randomised controlled trial
Schwartz KL, Shuldiner J, Langford BJ, Brown KA, Schultz SE, Leung V, Daneman N, Tadrous M, Witteman HO, Garber G, Grimshaw JM, Leis JA, Presseau J, Silverman MS, Taljaard M, Gomes T, Lacroix M, Brehaut J, Thavorn K, Gushue S, Friedman L, Zwarenstein M, Ivers N. BMJ. 2024; 385:e079329. Epub 2024 Jun 5.
Examining the impact of the COVID-19 pandemic on homecare services among individuals with traumatic and non-traumatic spinal cord injuries
Senthinathan A, Tadrous M, Hussain S, McKay S, Moineddin R, Chu C, Jaglal SB, Shepherd J, Cadel L, Noonan VK, Craven BC, Tu K, Guilcher SJT. Spinal Cord. 2024; May 29 [Epub ahead of print].
Characteristics of primary care practices by proportion of patients unvaccinated against SARS-CoV-2: a cross-sectional cohort study
Shuldiner J, Green ME, Kiran T, Khan S, Frymire E, Moineddin R, Kerr M, Tadrous M, Nowak DA, Kwong JC, Hu J, Witteman HO, Hamilton B, Bogoch I, Marshall LJ, Ikura S, Bar-Ziv S, Kaplan D, Ivers N. CMAJ. 2024; 196(13):E432-40. Epub 2024 Apr 8.
Alpha-1 adrenergic antagonists and the risk of hospitalization or death in non-hospitalized patients with COVID-19: a population-based study
Antoniou T, McCormack D, Tadrous M, Gomes T. Fundam Clin Pharmacol. 2024; Apr 4 [Epub ahead of print].
Trends in opioid toxicities among people with and without opioid use disorder and the impact of the COVID-19 pandemic in Ontario, Canada: a population-based analysis
Ledlie S, Tadrous M, Bayoumi AM, McCormack D, Cheng C, Besharah J, Munro C, Gomes T. Int J Drug Policy. 2024; Mar 23 [Epub ahead of print].
Varying circumstances surrounding opioid toxicity deaths across ethnoracial groups in Ontario, Canada: a population-based descriptive crosssectional study
Campbell TJ, Kitchen SA, Tadrous M, Damba C, Johnson CH, Smoke A, Crichlow F, Gomes T. BMJ Public Health. 2024; 2:e000480. Epub 2024 March 13.
A multiprovincial retrospective analysis of the incidence of myocarditis or pericarditis after mRNA vaccination compared to the incidence after SARS-CoV-2 infection
Naveed Z, Chu C, Tadrous M, Veroniki AA, Li J, Rouleau I, Febriani Y, Calzavara A, Buchan S, Nasreen S, Schwartz KL, Wilton J, Seo CY, Thampi N, Wilson S, Naus M, De Serres G, Janjua NZ, Kwong JC; Canadian Immunization Research Network (CIRN) Provincial Collaborative Network investigators. Heliyon. 2024; Feb 19 [Epub ahead of print].
Patterns of publicly funded naltrexone use among patients diagnosed with alcohol use disorder in Ontario
Tourchian N, McCormack D, Leece P, Tadrous M, Gomes T. Alcohol Alcohol. 2024; 59(2):agad091. Epub 2024 Jan 31.